CA-ALTIUM-LLC
3.3.2020 05:02:07 CET | Business Wire | Press release
TASKING, the embedded software division of Altium (ASX:ALU), today announced its new multi-core development environment for third-generation AURIX™ microcontrollers from Infineon. This capability will allow TASKING and Infineon automotive customers to optimize performance for multi-core architecture for safety-critical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302006089/en/
“Infineon and TASKING have a longstanding relationship in expansion of software development tools for Tricore™/AURIX™,” said Ralf Ködel, Director Product Marketing Microcontroller at Infineon, “With this new environment, TASKING provides an innovative one-stop shop solution for our customers.”
This upcoming AURIX™ family of microcontrollers will be prepared for data-hungry automotive applications such as future gateways, domain and zone controllers, engine management, electro-mobility, and advanced driver assistance systems. At the same time these microcontrollers will deliver the safety features, throughput, and power-efficient performance necessary to meet increasing AI computational requirements.
The new TASKING development environment is being developed according to Automotive SPICE® Level 2 standards, with plans for TÜV certification according to ISO 26262 up to ASIL D. This development environment provides compiler support for the new Parallel Processing Unit (PPU) from Synopsys, one of the main enhancements in the next generation AURIX™ family of microcontrollers, in addition to all instruction set architectures used in the next generation AURIX™ TC v1.8.
“These new capabilities from TASKING, empower our automotive customers to make safer traditional and autonomous vehicles, by providing them with a more expansive set of software development tools,” said Franz Maidl, Director Global TASKING Business. “This expansion also reinforces our relationship with Infineon as a partner of choice for Tricore™/AURIX™.”
About TASKING
TASKING is the embedded software division of Altium (ASX:ALU). TASKING development tools are used by automotive manufacturers and the world's largest Tier 1 suppliers to develop embedded microcontroller-based powertrain, body control, and Advanced Driver-Assistance Systems (ADAS) - related applications for both traditional and electric vehicles. These customers and those from adjacent industries, rely on the TASKING development tools to create richer next-generation applications while achieving optimum reliability, safety, and performance.
ABOUT ALTIUM
Altium LLC (ASX:ALU), a global software company headquartered in San Diego, Calif., is accelerating the pace of innovation through electronics. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.
The growing demand for smart and connected products is driving advancements in electronics technology. Design trends are demonstrating the need for minimizing power, reducing package size and energy consumption, and prioritizing high-speed design. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers, from idea to board. Users are at the center of Altium’s R&D and business operations. With its unique Business-to-User approach, Altium is focused on developing software that is easy to use and implement, with solutions that enable innovation and deliver industry-leading user productivity.
Products include Altium Designer®, Altium Concord Pro™, Altium 365®, Altium NEXUS®, CircuitMaker®, CircuitStudio®, Octopart®, and TASKING®. To learn more about Altium, visit www.altium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200302006089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom